OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive
Catalent Biologics announced a strategic agreement to develop and manufacture Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at a new commercial manufacturing center established by Paragon Gene Therapy, a unit of Catalent Biologics. Paragon Gene Therapy will also provide process development for clinical supply of additional viral therapies in the AveXis pipeline.